瑞科生物-B(02179.HK) 公布，近日收到中国证监会出具的《中国证监会行政许可申请受理单》。中国证监会依法对该公司提交的定向发行内资股申请材料进行审查，认为该申请材料齐全，决定对该行政许可申请予以受理。
截至周四(27日)，本次发行尚需满足该等公告及通函提及的先决条件，包括但不限于中国证监会的批准，因此仍存在不确定性。(js/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-27 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.